Class summary at a glance.

Every drug in the alpha-Glucosidase Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $10.4Mcombined across class
Total Rx claims: 267K83K unique beneficiaries
Generic mfrs (active): 7across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Acarbose

264K Part D claims (CY24) · 82K beneficiaries · First FDA approval: 2008-05-07

6 generic mfrs 0 plans require PA

Low NADAC$0.147

→

Avg plan cost$0.179

Part D spend $9.7M 1× spread, current vs floor

Class share

93%

of class CY24 spend

View profile →

Miglitol

2K Part D claims (CY24) · 724 beneficiaries · First FDA approval: 2021-01-15

1 generic mfrs 0 plans require PA

Low NADAC$1.75

→

Avg plan cost$1.75

Part D spend $725839 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.